18F-DCFPyL, a second generation 18F-labeled PSMA imaging agent, has been approved for use in men with prostate cancer by the FDA, and we posit that it may serve as a useful functional imaging agent for patients with HCC. Here, FOLH1 is linked to hepatocellular carcinoma.